4.5 Article

Treatment with LXR agonists after focal cerebral ischemia prevents brain damage

Journal

FEBS LETTERS
Volume 582, Issue 23-24, Pages 3396-3400

Publisher

WILEY
DOI: 10.1016/j.febslet.2008.08.035

Keywords

Acute cerebral ischemia; Experimental therapy; Neuroprotection; Nuclear receptor; Transcriptional activator

Funding

  1. American Diabetes Association
  2. American Heart Association

Ask authors/readers for more resources

Stroke is characterized by massive inflammation in areas surrounding the injury that magnifies damage to the brain. The liver X receptors (LXRs) are nuclear receptors that regulate cholesterol, lipid, and glucose metabolism. Synthetic LXR agonists have potent anti-inflammatory properties in a variety of settings, including neuroinflammation. However, the ability of LXR agonists to suppress stroke-associated inflammation has not been evaluated. Here, we have used time-lapse magnetic resonance imaging (MRI) to show that a single dose of an LXR ligand administered post-injury dramatically reduces brain damage in a model of acute brain ischemia. Neuroprotection was associated with suppression of neuroinflammation. (C) 2008 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available